Reinhart Partners LLC. Purchases New Stake in ICU Medical, Inc. $ICUI

Reinhart Partners LLC. acquired a new position in shares of ICU Medical, Inc. (NASDAQ:ICUI) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 314,768 shares of the medical instruments supplier’s stock, valued at approximately $46,148,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Millennium Management LLC boosted its position in shares of ICU Medical by 173.4% during the 3rd quarter. Millennium Management LLC now owns 1,089,017 shares of the medical instruments supplier’s stock worth $130,638,000 after purchasing an additional 690,694 shares in the last quarter. Norges Bank purchased a new position in shares of ICU Medical in the 4th quarter valued at about $58,083,000. Thrivent Financial for Lutherans lifted its stake in shares of ICU Medical by 1,604.0% in the fourth quarter. Thrivent Financial for Lutherans now owns 303,457 shares of the medical instruments supplier’s stock valued at $43,294,000 after purchasing an additional 285,648 shares during the period. UBS Group AG lifted its stake in shares of ICU Medical by 239.8% in the third quarter. UBS Group AG now owns 386,555 shares of the medical instruments supplier’s stock valued at $46,371,000 after purchasing an additional 272,782 shares during the period. Finally, Brown Advisory Inc. acquired a new position in ICU Medical during the fourth quarter worth about $32,445,000. Institutional investors and hedge funds own 96.10% of the company’s stock.

Key Stories Impacting ICU Medical

Here are the key news stories impacting ICU Medical this week:

• Positive Sentiment: Quarterly earnings beat expectations: ICU Medical reported second-quarter adjusted EPS of $2.37, up from $2.10 a year earlier and well above the $1.91 analyst consensus. Revenue reached $547.9 million versus expectations of $533.4 million, with infusion systems cited as a key growth driver. ICU Medical Q2 results beat analyst expectations, driven by infusion systems
• Positive Sentiment: Higher 2026 earnings outlook: The company raised or updated fiscal 2026 EPS guidance to $8.60–$9.00, above the approximately $7.83 consensus estimate. This indicates management expects stronger profitability than Wall Street previously modeled. ICU Medical Announces Second Quarter 2026 Results and Updates its Fiscal Year 2026 Guidance
• Positive Sentiment: Analysts raised price targets: Piper Sandler increased its target from $163 to $195 and maintained an “overweight” rating. Needham raised its target from $165 to $187 and reiterated a “buy” rating. The revisions reinforce the view that the earnings beat and guidance update improve ICU Medical’s growth outlook. ICU Medical Analysts Boost Their Forecasts Following Upbeat Q2 Earnings
• Neutral Sentiment: Valuation remains demanding: Despite the favorable earnings news, ICU Medical trades at a high earnings multiple, meaning further gains may depend on the company delivering against its elevated guidance and sustaining growth.

ICU Medical Stock Up 10.9%

Shares of NASDAQ ICUI opened at $184.56 on Friday. ICU Medical, Inc. has a 12-month low of $107.00 and a 12-month high of $192.85. The company has a market capitalization of $4.61 billion, a PE ratio of 156.41, a price-to-earnings-growth ratio of 2.32 and a beta of 0.74. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.34 and a quick ratio of 1.17. The firm’s 50-day moving average is $151.64 and its two-hundred day moving average is $141.02.

ICU Medical (NASDAQ:ICUI) last issued its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $2.37 earnings per share for the quarter, topping analysts’ consensus estimates of $1.91 by $0.46. ICU Medical had a net margin of 1.39% and a return on equity of 7.94%. The business had revenue of $547.88 million during the quarter, compared to analysts’ expectations of $533.44 million. During the same period last year, the company posted $2.10 EPS. The company’s revenue was up .5% on a year-over-year basis. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. Equities analysts anticipate that ICU Medical, Inc. will post 6.51 EPS for the current fiscal year.

Insider Buying and Selling at ICU Medical

In other news, Director David C. Greenberg sold 2,424 shares of the company’s stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $122.91, for a total value of $297,933.84. Following the sale, the director directly owned 7,960 shares in the company, valued at $978,363.60. This represents a 23.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Virginia Ruth Sanzone sold 2,447 shares of the firm’s stock in a transaction dated Thursday, May 14th. The stock was sold at an average price of $124.08, for a total transaction of $303,623.76. Following the sale, the vice president directly owned 19,460 shares in the company, valued at $2,414,596.80. This represents a 11.17% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 2.10% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

ICUI has been the subject of a number of research analyst reports. Zacks Research cut shares of ICU Medical from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 28th. Raymond James Financial restated a “strong-buy” rating and issued a $200.00 price target on shares of ICU Medical in a report on Friday. Piper Sandler raised their price objective on ICU Medical from $163.00 to $195.00 and gave the company an “overweight” rating in a research note on Friday. Sanford C. Bernstein cut ICU Medical to a “market perform” rating in a report on Monday, June 15th. Finally, BTIG Research boosted their target price on ICU Medical from $170.00 to $200.00 and gave the stock a “buy” rating in a research report on Friday. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $192.80.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.